Dopamine modulates male sexual behavior in Japanese quail in part via actions on noradrenergic receptors.
In rats, dopamine (DA) facilitates male sexual behavior through its combined action on D1- and D2-like receptors, in the medial preoptic area (MPOA) as well as other brain areas. In Japanese quail, systemic injections of dopaminergic drugs suggested a similar pharmacology but central injections have never been performed. Recent electrophysiological experiments demonstrated that DA effects in the MPOA of quail are mediated mainly through the activation of alpha2-noradrenergic receptors. Previous studies of DA action on behavior used specific dopaminergic agonists/antagonists and therefore unintentionally avoided the potential cross-reaction with alpha2-receptors. The present study was thus designed to investigate directly the effects of DA on male sexual behavior and to test whether the interaction of DA with heterologous receptors affects this behavior. Intracerebroventricular (i.c.v.) injection of DA or NE inhibited copulation in a dose-dependent manner. Systemic injections of yohimbine, an alpha2-noradrenergic antagonist, modulated copulation in a bimodal manner depending on the dose injected. Interestingly, a behaviorally ineffective dose of yohimbine markedly reduced the inhibitory effects of DA when injected 15min before. Together, these results show for the first time that i.c.v. injections of DA itself inhibit male sexual behavior in quail and suggest that the interaction of DA with alpha2-receptors has behavioral significance.
Cornil
Charlotte A
CA
Center for Cellular and Molecular Neurobiology, Research Group in Behavioral Neuroendocrinology, University of Liège, B-4020 Liège, Belgium. ccornil@jhu.edu
Dejace
Christel
C
Ball
Gregory F
GF
Balthazart
Jacques
J
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000704:Analysis of Variance; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001141:Aromatase / Q000378:metabolism; D003370:Coturnix / Q000502:physiology*; D004298:Dopamine / Q000008:administration & dosage / Q000378:metabolism*; D018491:Dopamine Agonists / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D007276:Injections, Intraventricular; D008297:Male; D008845:Microinjections; D009638:Norepinephrine / Q000008:administration & dosage / Q000378:metabolism*; D011301:Preoptic Area / Q000187:drug effects / Q000378:metabolism; D018341:Receptors, Adrenergic, alpha-2 / Q000187:drug effects / Q000378:metabolism*; D012726:Sexual Behavior, Animal / Q000187:drug effects / Q000502:physiology*; D020542:Third Ventricle; D015016:Yohimbine / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D018491:Dopamine Agonists; D018341:Receptors, Adrenergic, alpha-2; D015016:Yohimbine; D001141:Aromatase; D001058:Apomorphine; D004298:Dopamine; D009638:Norepinephrine